Feature

Video

2024 AUA preview: Dr. Elterman on key research in BPH

Dean S. Elterman, MD, MSc, FRCSC, highlights several studies in BPH being presented at the 2024 AUA Annual Meeting.

In this video, Dean S. Elterman, MD, MSc, FRCSC, highlights 4 studies in benign prostatic hyperplasia (BPH) that will be presented at the upcoming 2024 American Urological Association (AUA) Annual Meeting, which will take place on May 3 – 6 in San Antonio, Texas. Elterman is a urologist at the University of Toronto in Canada.

Elterman previewed the following abstracts:

  • MP46-02 (Roehrborn et al): The Early Patient Experience Following Treatment with PUL and WVTT, Two Contemporary MISTs for BPH: Preliminary Results from the CLEAR Study
  • MP06-15 (Elliott et al): The Optilume® Drug Coated Balloon for recurrent anterior urethral strictures: ROBUST III study 4-year interim results
  • MP46-04 (Cerrato et al): Rezum for BPH: results from a large retrospective multicenter study
  • MP27-01 (Gilling et al): 24-Month Outcomes from the ZEST Pilot studies of the Zenflow Spring System for the Treatment of Benign Prostatic Hyperplasia (BPH)
Related Videos
Alexander Pastuszak, MD, PhD: Is hormone therapy safe after prostate cancer radiotherapy?
Refining prostate cancer therapy strategy to address RAPTOR findings
Considering patient-reported outcomes in kidney cancer care, with Nicholas Zaorsky, MD, PhD
Soumyajit Roy, MS, MBBS: The effect of prostate cancer patient history in RAPTOR
 Nicholas Zaorsky, MD, MS: Protecting kidney function after local renal cell carcinoma therapy
Nicholas van AS, MD, MBBCH: The case for SBRT as a standard of care for localized prostate cancer
Pierre Blanchard, MD, PhD: What can hydrogel space provide to optimal prostate cancer care?
Savita Dandapani, MD, PhD: Findings from the phase 2 SHARP trial
Related Content
© 2024 MJH Life Sciences

All rights reserved.